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Abstract 
Background: CHI3L1 is a chitinase-like protein without enzymatic activity, produced by activated macrophages, 
chondrocytes, neutrophils. Recent studies on arthritis, asthma, and inflammatory bowel diseases suggest that chi-
tinases are important in inflammatory processes and tissue remodeling, but their production by human T cells, has 
never been reported.
Methods: A microarray analysis of gene expression profile was performed on Th17 and classic Th1 cell clones and 
CHI3L1 was found among the up-regulated genes on Th17 cells. Different types of helper T cell clones (TCCs) were 
then evaluated by Real Time PCR (RT-PCR) for CHI3L1 mRNA expression; protein expression was investigated in cell 
lysates by western blotting and in cultures supernatants by ELISA. ELISA was also used to measure CHI3L1 in the 
serum and in the synovial fluid (SF) of juvenile idiopathic arthritis (JIA) patients.
Results: At mRNA level CHI3L1 was highly expressed by Th17, Th17/Th1, non classic Th1 and even in Th17/Th2 cell 
clones, whereas it was virtually absent in CD161− classic Th1 and Th2 TCCs. CHI3L1 was also detected in cell culture 
supernatants of Th17 and Th17-derived cells but not of classic Th1. Moreover CHI3L1 was higher in the SF than in 
serum of JIA patients, and it positively correlated with the frequency of Th17 and non-classic Th1 cells in SF. CHI3L1 in 
SF also positively correlated with the C reactive protein (CRP) serum levels, and with the levels of some proinflamma-
tory cytokines, such as IL-6 and p40, which is the common subunit of IL12 and IL23.
Conclusions: Here we describe for the first time CHI3L1 production by T cells owing the Th17 family. Moreover the 
positive correlation found between the frequency of Th17 and Th17-derived cell subsets and CHI3L1 levels in SF of JIA 
patients, in agreement with the suggested role of these cells in inflammatory process, candidates CHI3L1 as a possible 
biological target in JIA treatment.
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Background
Chitinases belong to a family of hydrolases, the glyco-
syl hydrolase 18 proteins (GH18), characterized by the 
ability to cleave the environmental polysaccharide chi-
tin, present in the coating of many pathogens including 
protozoan parasites, fungi, and nematodes. Although 
mammals do not synthesize chitin, they do synthesize 
chitinases and chitinase-like proteins (CLPs), that, due 
to mutations in their active domain, don’t have chitino-
lytic enzyme activity. Members of this family include 
chitinase 3-like-1 (also known as YKL-40 or HC-gp39) 
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[1], chitotriosidase [2], YKL-39 [3], Ym1 [4], acidic mam-
malian chitinase (AMCase) [5], oviduct-specific gly-
coprotein [6], and stabilin-1-interacting chitinase-like 
protein [7]. The physiological role of these secretory 
proteins remains unclear and debated, even if recent 
findings strongly support the concept that chitinases 
and CLPs are induced at sites of infection as part of an 
innate anti-pathogen response: in that context they are 
described to act by controlling tissue injury and spe-
cific innate immune response such as those induced 
by chitin fragments and augmenting adaptive immune 
responses, ensuring pathogen eradication [8]. The major-
ity of the glycosyl 18-hydrolase family member are CLPs 
and among them chitinase 3-like-1 (CHI3L1) is the most 
studied: it is endogenously expressed by several cell types 
including macrophages, neutrophils, chondrocytes, 
fibroblasts, endothelial cells and colonic, ductal, and air-
way epithelial cells [1, 8]. CHI3L1 expression is upregu-
lated during inflammatory conditions when it is essential 
for mounting Th2-type immune responses, stimulating 
dendritic cell accumulation/activation and recruitment 
of macrophages but also for inhibiting eosinophils, mac-
rophages and T cells death-receptor mediated, apoptosis 
[9]. CHI3L1 has been also shown to stimulate prolifera-
tion of human connective tissue cells through a MAPK/
AKT dependent pathway [10]. In agreement with these 
evidences on CHI3L1 activities, KO mice have been gen-
erated that developed less severe inflammatory responses 
at the acute phase of bacterial infectious colitis [11] as 
well as suppressed Th2-type immune responses, charac-
terized by lower tissue inflammation, fibrosis and higher 
immune cell apoptosis [9]. Increased levels of CHI3L1 
protein and/or mRNA have been shown in patients with 
a broad spectrum of diseases including asthma [9, 12], 
inflammatory bowel disease (IBD) [13, 14] and arthritis 
[15, 16] where they reflect the activity and natural his-
tory of the disease. In fact, genetic variation of CHI3L1 
gene associated with its higher expression in serum and 
with exacerbation of asthma and airways tissue remodel-
ling [17]. Finally CHI3L1 has been proposed as a candi-
date autoantigen in rheumatoid arthritis (RA) [18] due to 
its different expression in cartilage and synovial tissues, 
and to a possible link with the human leukocyte anti-
gen (HLA)-DR4 shared epitope [19]. As a result of this 
knowledge CHI3L1 is already considered a prognostic 
biomarker for several immune mediated diseases and has 
been proposed to be a therapeutic target in conditions 
characterized by fibrosis, extracellular matrix remodeling 
and acute or chronic inflammation [12, 14–16].
It is already well described that T helper populations, 
in addition to their protective role, are involved in sev-
eral chronic inflammatory immune-mediated disorders. 
CD4+ T helper (Th) cells can be classified into lineages 
on the basis of the cytokines production, the specific 
transcription factors expression and the immune-physi-
ological function they mediate. Th1 cells, which express 
the transcription factor T-box expressed in T cells (T-bet) 
and secrete IFN-γ, protect the host against intracellular 
infections; Th2 cells, which express GATA-3 and secrete 
IL-4, IL-5 and IL-13, mediate host defense against hel-
minths [20, 21]. Recently, additional subsets that prefer-
entially produce distinct cytokines have been described. 
The most studied subset includes cells that selectively 
produce IL-17A (Th17 cells), express the transcription 
factor RAR-related orphan receptor (ROR)γt, the IL-23 
receptor (IL-23R), the chemokine receptor CCR6 and the 
lectin receptor CD161 and protect the host against extra-
cellular pathogens infections [22–24]. Human Th17 cells 
originate from CD161+ precursors present in umbilical 
cord blood (UCB) and new born thymus, and maintain 
CD161 expression, that is detectable on memory circu-
lating and tissue-infiltrating Th17 lymphocytes [24–26]. 
Th17 lymphocytes, beyond their protective role in the 
clearance of extracellular pathogens, also play a role in 
the pathogenesis of several autoimmune and inflamma-
tory diseases [27]. In particular, a determinant role for 
Th17 cells has been proposed in multiple sclerosis, RA 
and IBDs, but also in psoriasis and contact dermatitis 
[28, 29], under-evaluating the contribution of Th1 cells 
[30], previously shown to be crucial. Although classically 
viewed as distinct lineages, recent evidence indicate that 
Th17 cells are more plastic than previously thought. It 
is not fully understood how often such plasticity occurs 
in the course of physiologic responses to pathogens and 
what its importance is in protective immunity, but in 
inflammatory conditions Th17 lymphocytes, that have 
shifted towards a Th1 or Th2 phenotype maintaining 
CD161 and RORc expression and acquiring the ability to 
produce IFN-γ or IL-4, seem to be particularly aggressive 
and more pathogenic than the unshifted ones [31, 32]. In 
a recent study, we found that Th17 cells are rare in the SF 
of patients with JIA whereas Th1 cells were highly pre-
dominant, which was at least partially due to the prop-
erty of Th17 cells to shift into Th1 cells in presence of 
IL-12, and/or TNF-α [33, 34]. The Th17-derived Th1 cells 
expressed CD161, while the other Th1 cells present in the 
SF did not, and we named the former cells as non-classic, 
as compared with classic CD161− Th1 cells [33]. Moreo-
ver, we found an accumulation of Th17 and non-classic 
CD161+ Th1 lymphocytes in fistula curettage of patients 
suffering of fistulising Crohn’s disease [35, 36]. Another 
evidence of the high plasticity of human Th17 cells also 
emerges by the recent finding of the existence of a subset 
of human circulating memory CD4 T cells that produce 
both IL-17A and IL-4 [31]. This previously unknown 
population of Th17/Th2 lymphocytes maintains CD161 
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membrane expression, is more represented in the cir-
culation of patients with allergic asthma than in healthy 
donors, and is enriched in cells specific for the sensitizing 
allergen, suggesting a possible role in the pathogenesis 
of the disease [31]. In the present study, we found that 
human Th17, and non-classic Th1 cells are able to pro-
duce CHI3L1, whereas classic Th1 cells are not. In agree-
ment with the suggested role in inflammatory processes 
we also found CHI3L1 in the SF of JIA patients, which 
positively correlated to the inflammatory status. These 
data open new insights about the possible involvement 
of CHI3L1 in those chronic inflammatory disorders in 
which Th17 subsets play a pathogenic role.
Methods
Reagents
The culture media used was RPMI 1640 (Seromed) sup-
plemented with 2  mM l-glutamine, 1% non-essential 
amino acids, 1% sodium pyruvate, 2  ×  10−5 M 2-mer-
captoethanol (2-ME; all from Invitrogen), and 10% FBS 
HyClone (Gibco Laboratories, Grand Island, NY). Unla-
beled or fluorochrome-conjugated anti- CD3, CD4, CD8, 
CD161, CCR6, IFN-γ, and isotype-matched control mAb 
were purchased from BDBiosciences (San Jose, CA, 
USA). The fluorochrome-conjugated anti-IL-17 mAb 
was obtained from eBioscience (San Diego, CA, USA) 
and the fluorochrome-conjugated anti-CXCR3 mAb was 
obtained from R&D Systems (Minneapolis, MN, USA). 
PMA, ionomycin and brefeldin A were purchased from 
Sigma Chemical Co. (St. Louis, MO, USA). Activating 
mAb anti-CD3 and -CD28 were purchased from BDBio-
sciences (San Jose, CA, USA).
Establishment of T cell clones and their characterization
CD4+ T cells, derived from PBMNC of healthy donors 
by using the CD4 isolation kit II (Miltenyi Biotec, Ber-
gisch Gladbach), were further divided into CD161+ 
and CD161− T-cell fractions by a staining with an anti-
CD161–PE mAb, followed by incubation with an anti-PE 
microbead mAb (Miltenyi Biotec). Then the two cell sub-
sets CD4+CD161+ and CD4+CD161− were cultured 
under limiting dilution (0.3 cell/well) in presence of 105 
irradiated (9000  rad) allogeneic PBMCs as feeder cells, 
1% PHA (vol/vol), and 50  U/ml rIL-2 (Proleukin, Pro-
metheus, Inc. San Diego, USA), in order to obtain T cell 
clones. Recovered CD4+ T cell clones were classified on 
the basis of their ability to produce IFN-γ and/or IL-17 
and to express surface marker CD161, as previously 
described [24]. Briefly, T cells were polyclonally stimu-
lated with PMA plus ionomycin, fixed in formaldehyde 
and then analyzed for intracellular cytokines production 
on a BDLSR II flow cytometry (BDBiosciences). Selected 
T-cell clones of each phenotype were further analysed 
by flow cytometry for surface expression of CXCR3A 
and CCR6. Seven Th17, non-classic -Th1 and classic Th1 
clones were stimulated at a culture concentration of 106 
cells/ml for 72  h in presence of medium or mAbs anti- 
anti-CD3-CD28 (5  μg/ml each), then cultures super-
natants were collected and stored at −30  °C for further 
analysis.
Microarray
Gene expression profiles on human Th17, classic and 
non-classic Th1 clones were assessed by cDNA microar-
ray technique using the Human Genome Survey Micro-
array (Applied Biosystems). In brief, RNA from different 
samples was amplified and labeled with Digoxigenin-
UTP (DIG-UTP; Applied Biosystems). 10  μg of DIG-
labeled cRNA was hybridized to the Human Genome 
Survey Microarray and read using the 1700 Chemilu-
minescent Microarray Analyzer (Applied Biosystems). 
Expression Array System software (Applied Biosystems) 
was used to analyze the microarrays images. Only micro-
arrays showing a normalized signal intensity >5000 and a 
median background <600 were analyzed and normalized 
using Spotfire and Intergomics software (Spotfi re Inc.). 
Class comparisons expressed as Benjamini–Hochberg 
false discovery rates were done using parametric tests 
(LIMMA) after log transformation. Each sample was ana-
lyzed three times. Microarray data are available from the 
Gene Expression Omnibus database (http://www.ncbi.
nlm.nih.gov/gds) under the accession number GSE30664.
Real‑time quantitative RT‑PCR
Taq-Man RT-PCR was performed, as described else-
where [24]. Quantitative PCR analysis of CHI3L1 was 
performed by using primers and probes purchased from 
Applied Biosystems (Warrington, UK). Quantification 
was performed on cell number.
Western Blot analysis
T Cell lysates were prepared in lysis buffer (RIPA buffer: 
25 mM Tris–HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS and 5 mM EDTA) con-
taining a protease- and phosphatase-inhibitor mixture 
(Pierce). Proteins were quantified by Bradford Assay 
before equivalent amounts were separated by SDS-
PAGE were run on a 4–20% polyacrylamide gel (Bio-
Rad, USA) for 2 h at 120 V, transferred to a nitrocellulose 
membrane for 16 h at 30 V, blocked in 5% milk for 1 h 
at room temperature. CHI3L1 protein expression was 
detected by anti-human CHI3L1 rabbit-pAb (ab88847; 
Abcam) administered for 18  h followed by incubation 
with horseradish peroxidase–conjugated anti-rabbit pAb 
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(Santa-Cruz biotechnology) for 1 h at room temperature. 
An enhanced chemiluminescent substrate (GE Health-
care) for detection of HRP was used for visualization.
Subjects
Samples of PB and SF were obtained from 25 children, 
15 average aged, with oligoarticular-onset JIA, whose 
diagnosis was made in accordance with the Interna-
tional League of Associations for Rheumatology classifi-
cation criteria for JIA [37]. Patients with systemic-onset 
disease, polyarticular JIA, or enthesitis-related arthritis 
were excluded, in order to assess a homogeneous patient 
group. The C-reactive protein (CRP) serum levels (nor-
mal values up to 0.5 mg/dl), assessed using the particle-
enhanced turbidimetric immunoassay method, were 
evaluated by staff in the service laboratory of the Anna 
Meyer Pediatric Hospital in Florence, Italy.
The procedures followed in the study were in accord-
ance with the ethics standards of the Regional Commit-
tee on Human Experimentation. Informed consent was 
obtained by parents or guardians.
Quantitative detection of CHI3L1
CHI3L1 levels in the culture supernatants, sera and SF of 
JIA patients were assessed using a commercially available 
ELISA kit by R&D Systems. Assays were performed fol-
lowing manufacturer’s instructions.
Enzyme‑linked immunosorbent assays (ELISAs)
All the cytokines analyzed in the sera and SF of JIA 
patients were assessed using a Custom LEGENDplex 
ELISA kit from BioLegend whereas the detection of 
IL12p40 levels was done by an ELISA kit from Invitrogen.
Statistical analysis
A non-parametric Mann–Whitney test, performed by 
Origin Pro 2015 software, was used for statistical analy-
sis. p values less than or equal to 0.05 were considered 
significant. Pearson’s correlation coefficients were used to 
calculate the correlations.
Results
CHI3L1 is produced by non‑classic Th1 and Th17 clones
In previous studies, we generated a series of classic Th1 
and Th17 clones from circulating CD4+ T cells obtained 
from healthy donors. In order to identify the differences 
in the gene expression profile between Th17 and classic 
Th1 clones, a microarray analysis was performed [24, 26, 
38, 39]. Among genes that fulfilled the criteria described 
in the Methods section as up- or down-regulated genes 
in Th17 versus classic Th1 clones, in addition to those 
expected on the basis of previous knowledge, such as, 
RORγt, CCR6, CXCR3, CD161, IL-17, IL-23R and IL4I1 
[40, 41], there was also CHI3L1 (Fig.  1a). Therefore, 
CHI3L1 expression was analysed by quantitative-RT PCR 
and extended to a new panel of human Th17, Th17/Th1, 
non-classic Th1, Th17/Th2 and Th2 clones, derived from 
healthy subjects. As shown in Fig.  1b, Th17, Th17/Th1, 
non-classic Th1 and Th17/Th2 clones expressed signifi-
cantly higher levels of CHI3L1 mRNA than classic Th1 
and Th2 clones.
Based on the results obtained at mRNA level, we first 
assessed CHI3L1 expression at protein level by western 
blot analysis on resting TCCs lysates, confirming that 
Th17 and non-classic Th1 clones express CHI3L1 while 
classic Th1 did not (Fig.  2a). Then, in order to under-
stand if Th17 and Th17-derived T cells, like non-classic 
Th1 clones were also able to secrete CHI3L1, TCCs of 
Fig. 1 CHI3L1 is expressed by Th17 and Th17-derived cells. a Volcano 
plot representation (log fold change vs. −log 10 p value) of Th17 and 
classic Th1 cells gene expression profiles. b CHI3L1 mRNA expression 
was evaluated by real time quantitative RT-PCR on Th17 (n = 14), 
Th17/Th1 (n = 7), non classic Th1 (n = 9), Th17/Th2 (n = 8), Th2 
(n = 5) and classic Th1 (n = 15) clones. Columns represent mean 
values (±SE). *p ≤ 0.05 compared to classic Th1 column; **p ≤ 0.05 
compared to Th2 column
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each phenotype were cultured in  vitro for 72  h in the 
absence or presence of anti-CD3 plus anti-CD28 mAbs 
or PMA plus ionomycin and the cell culture superna-
tants collected. As shown in Fig. 2b, Th17 and non-classic 
Th1 clones produced comparable amounts of CHI3L1 
independently of anti-CD3 plus anti-CD28 mAbs or 
PMA ionomycin stimulation, whereas, accordingly to 
mRNA data expression, classic Th1 cells did not pro-
duce CHI3L1. Interestingly we observed a reduction in 
CHI3L1 production by both Th17 and non-classic Th1 
cells in the stimulating conditions (Fig. 2b).
The amount of CHI3L1 present in the SF of JIA patients 
positively correlates with the frequency of Th17 cells
It has been shown that, in RA patients serum, CHI3L1 
levels positively correlated with levels of C reactive pro-
tein (CRP) [42, 43]. We have recently shown that the fre-
quency of CD4+CD161+, found among CD4+ T cells 
present in the SF of JIA patients, positively correlates 
with the levels of two inflammatory parameters, such 
as the erythrocytes sedimentation rate (ESR) and the 
CRP, measured in the sera of the same patients [33]. In 
order to understand if CHI3L1 produced by Th17 cells 
may play a role in JIA pathogenesis, we evaluated both 
the CHI3L1 levels and the frequencies of the different T 
helper cell populations in the synovial fluid of a cohort 
of 25 JIA patients. As shown in Fig.  3a, the CHI3L1 
amounts present in the SF were significantly higher than 
those observed in the sera of the same patients. Moreo-
ver, and more importantly, the CHI3L1 amounts present 
in the SF of JIA patients positively correlated with the fre-
quencies of Th17 (Fig. 3b) and non-classic Th1 (Fig. 3c) 
cells, but not with the classic Th1 (Fig. 3d) cells. Finally 
CHI3L1 quantity in the SF of JIA patients positively cor-
related with the CRP levels present in the sera of the 
same patients (Fig. 3e). To further strengthen the associa-
tion between CHI3L1 levels and the inflammatory status, 
we checked if these levels correlate also with inflamma-
tory cytokines, in SF. To this end we firstly compared 
the levels of inflammatory cytokines in peripheral blood 
and SF of JIA patients (Fig. 3f ). Among the inflammatory 
cytokines that resulted to be more expressed in SF than 
PB, we found a positive correlation of CHI3L1 levels with 
both IL6 and the p40 chain (Fig. 3g).
Discussion
In this paper we detected for the first time the expres-
sion of CHI3L1 in human T cells. As a result of a gene 
expression profile microarray analysis on T cell clones 
we unexpectedly found that CHI3L1 was one of the most 
up-regulated genes, together with other described (i.e. 
CCR6 and RORc), in resting Th17 clones when compared 
to classic Th1. We and others already assessed that the 
frequencies of CD161+ Th17-derived Th1, Th17/Th1 
and Th17/Th2, cells, positively correlated with severe 
phenotype of different chronic inflammatory disorders 
such as JIA, IBDs and asthma, respectively [31–36]. In 
the same pathological conditions higher levels of CHI3L1 
have been detected in patients’ serum respect to healthy 
donors [14–16]. Based on this knowledge CHI3L1 mRNA 
expression was evaluated confirming the microarray data. 
We found that CHI3L1 mRNA was selectively expressed 
by human Th17, Th17/Th1, non-classic Th1, and Th17/
Th2, cells but not by their CD161− counterparts. This 
finding means that CHI3L1 is expressed only by CD161+ 
cells. Of note, mRNA amounts of CHI3L1 were highest 
on pure Th17 cells and showed a trend to decrease in the 
other CD161+ subsets, suggesting that it could represent 
a sort of marker of Th17 lymphocytes. The finding that 
Th17/Th2 cells express high levels of CHI3L1 is in agree-
ment with the possible pathogenic role of these cells in 
neutrophilic steroid-resistant asthma since both Th17/
Th2 and serum levels of CHI3L1 result to be increased in 
such disease [42–44].
In the second part of the study, we focused on the three 
cell subsets Th17, non-classic Th1, as the main exam-
ple of Th17-derived phenotype, and classic Th1 cells, 
performing western blot analysis of CHI3L1 protein 
expression on resting T cell lysates. Results showed an 
evident expression of CHI3L1 on Th17 cells even if on 
Fig. 2 CHI3L1 protein is secreted by Th17 and non-classic Th1 cells. 
a CHI3L1 protein (40 kDa) expression was evaluated on cell lysates of 
Th17, non classic-Th1 and classic-Th1 clones by western blot analysis. 
b Secreted CHI3L1 was measured on cell culture supernatants of 
Th17 (n = 7), non classic Th1 (n = 7) and classic Th1 (n = 7) clones 
after 72 h stimulation with medium (white columns), anti-CD3/CD28 
mAbs (grey columns) or PMA plus Ionomycin (black columns) by 
ELISA. Columns represent mean values (±SE). *p ≤ 0.05
Page 6 of 9Capone et al. Clin Mol Allergy  (2016) 14:16 
Page 7 of 9Capone et al. Clin Mol Allergy  (2016) 14:16 
non-classic and classic Th1 it seemed virtually absent. 
This was apparently in contrast with the data obtained 
at mRNA level and in order to explain this discrepancy 
we moved to investigate CHI3L1 level cultures superna-
tants. CHI3L1 levels were measured by ELISA on super-
natants obtained by culturing Th17, non-classic Th1 and 
classic Th1 clones in presence or absence of two types 
of polyclonal stimulus (mAbs anti-CD3/CD28 or PMA 
plus ionomycin). As expected CHI3L1 was produced 
only by Th17 and non-classic Th1 cell cultures whereas 
in classic Th1 ones it was not detected. This discrepancy 
between western blot analysis and ELISA, could be due 
to the fact that CHI3L1 is a secreted protein. Probably 
in Th17 cells it is anyway detectable, because it is stored 
in the intracellular compartment, whereas the same did 
not occur in non-classic Th1 cells where the amounts 
are lower. Recent studies demonstrated that increased 
levels of CHI3L1 in synovial fluid and serum have been 
found in patients with active RA compared to patients 
with inactive RA and healthy subjects, and changes in 
serum CHI3L1 during drug therapy reflect changes in 
disease activity. Moreover, in patients with early RA, a 
continuously elevated serum CHI3L1 is associated with 
progression of joint destruction [15, 16]. Given this lit-
erature we deepened our results on TCCs and consider-
ing our previous evidences on the involvement of Th17 
and Th17-derived Th1 cells in JIA pathogenesis [33] we 
searched for any possible correlation between them 
and CHI3L1 expression. To this end we first assessed 
CHI3L1 levels on sera and synovial fluids from several 
JIA patients and showed that they are significantly higher 
at the inflamed tissue when compared to the periphery, 
thus confirming literature data on rheumatoid arthritis 
[45, 46]. Moreover we characterized SF for the presence 
of CD161-expressing cells and found that the frequencies 
of CD161+IL17− or IFNγ− producing cells positively 
correlated to CHI3L1 levels. This led us to hypothesize 
that CHI3L1 production by Th17 and non-classic-Th1 
cells may be somehow related to their pathogenic role in 
JIA. Accordingly, in the same patients CHI3L1 levels in 
the synovial fluid were also positively correlated with the 
inflammatory status evaluated by CRP. Moreover, also 
the levels of proinflammatory cytokines, such as IL6 and 
the p40 chain, positively correlated with CHI3L1 in SF. 
The p40 chain is the common subunit of IL12 and IL23, 
whose role in the induction of the Th1 (both classic and 
non-classic) and Th17 effectors has been clearly shown 
[24]. In this view the finding of p40 overexpression in SF 
was not surprising, and in agreement with the proposed 
role of these T cell subset in JIA pathogenesis.
Our data are in agreement with the most accepted 
concept of CHI3L1 as a marker of disease activity and 
inflammation in several immune-mediated disorders. 
The previously unknown information that CHI3L1 is 
produced by Th17 and Th17-derived cells, open new 
insights on the possible role of this molecule in those 
inflammatory diseases in which these T cell subsets play 
a pathogenic role.
Conclusion
CHI3L1 is produced by Th17 and non-classic Th1 cells, 
already demonstrated to exert a role in the pathogenesis 
of JIA. CHI3L1 levels on SF from JIA patients positively 
correlated with frequencies of Th17-derived cells, with 
CRP levels and with the levels of IL6 and the p40 IL12/
IL23 subunit in SF. These findings suggest a possible 
involvement of CHI3L1 in mediating joint inflammation 
in JIA. Based on these findings CHI3L1 could be consid-
ered a possible biological target for medical treatment of 
JIA.
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Fig. 3 CHI3L1 levels positively correlate with the frequency of CD161+ cells in the SF of JIA. PB and SF from 25 JIA patients were evaluated: sera from 
peripheral blood (white columns) and SF (black columns) were obtained and CHI3L1 amounts evaluated by ELISA (a). Columns represent mean values 
(±SE). *p ≤ 0.05. MNC cells obtained from SF were characterized by flow cytometry and correlation between CHI3L1 levels in SF and frequency of 
CD4+CD161+IL17+ cells (b), CD4+CD161+IFNγ+ cells (c) and CD4+CD161−IFNγ+ cells (d), in SF, was represented. e Correlation between CHI3L1 
levels in SF and CRP serum levels in the same group of patients. f The indicated cytokines were assessed in the sera (white columns) and SF (black 
columns) from 25 JIA patients. Columns represent the mean values (±SE). *p ≤ 0.05. g Correlation between CHI3L1 levels in SF and IL6 (left panel) or 
p40 (right panel) SF levels in the same group of patients, was represented
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